Bristol Myers Squibb and PicnicHealth partner on real-world data

By Ben Hargreaves

- Last updated on GMT

PicnicHealth and Bristol Myers Squibb partner to generate real-world evidence for patients receiving specifically receiving Camzyos (mavacamten)    Image © Prostock-Studio / Getty Images
PicnicHealth and Bristol Myers Squibb partner to generate real-world evidence for patients receiving specifically receiving Camzyos (mavacamten) Image © Prostock-Studio / Getty Images

Related tags: Bristol Myers Squibb, Real world data

The two companies will combine real-world datasets to better understand marketing treatment with Bristol Myers Squibb’s drug in a post-marketing setting.

PicnicHealth and Bristol Myers Squibb partner to generate real-world evidence for patients receiving specifically receiving Camzyos (mavacamten), or other non-specified treatment.

The aim is to line up a database of data to complement BMS’ existing Discover-HCM registry, which already contains the detail of 1,500 consenting patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).

Through the partnership, the companies stated that PicnicHealth’s platform will allow patient participants to access their own medical information aggregated in a single location.

PicnicHealth is a healthcare technology company that uses consenting patients’ medical records to build real-world datasets. The company is able to use machine learning, alongside human curation, to turn complete medical records into an online application.

Once the datasets are built, patients are given access to and control over their medical records, which can then, with consent, be provided to other research-based organizations.

Noga Leviner, CEO of PicnicHealth, stated that it can be difficult to attain a clear understanding of patients’ experience within the US healthcare system. The company is able to make this clearer through its real-world patient data, as it gives access to the study sponsor of the patients’ complete medical records, providing an improved understanding of patient experiences and outcomes.

The specific use case for BMS will be to provide historical and prospective medical information including emergency room visits, hospitalizations, care at other clinics and other medical events, which will be used to supplement BMS’ registry data.

The Discover-HCM registry will evaluate the safety, treatment pattern, short- and long-term outcomes, and healthcare resource utilization of patients in US with symptomatic oHCM. More particularly, the study will assess the real-world safety and effectiveness of Camzyos in patients with the condition.

According to the companies, the registry data and PicnicHeath’s real-world data will be used to provide the investigator with a better understanding of participants’ complete medical journeys, including medication use, comorbidities, and past medical procedures.

PicnicHealth stated that the results in the Discover-HCM study will inform how using patient-centric data collection from routine medical care can improve how long-term, post-marketing studies are performed, as well as providing a greater understanding of the risks and benefits of treatments in the real world.

In June 2022, PicnicHealth raised $60m (€58.7m) through a Series C financing round led by B Capital Group, bringing the total raised by PicnicHealth to more than $100m.

The company said at the time that funds would be used to grow its portfolio of real-world data cohorts across 30 new indications in complex, chronic, or rare conditions.

Related topics: Markets & Regulations

Follow us

Products

View more

Webinars